Overview

Monroe Biomedical Research was acquired by New Harbor Capital in a first step to build-out a clinical research site platform.

Significance

Specialized research sites that possess diverse therapeutic proficiencies and diverse patient populations play a pivotal role in effectively introducing novel drugs and treatments to the market. These sites provide comprehensive support services that encompass patient recruitment, regulatory adherence, and expedited data collection. By operating within condensed timelines, these facilities guarantee the streamlined execution of trials, and their adeptness proves invaluable for sponsors as they navigate the intricate pathways of clinical development. The contributions of these clinical research sites are paramount in propelling public health advancements on a worldwide level.

Since 2016 Monroe Biomedical Research (“MBR”) has built an expansive clinical research database that is committed to diversity as a research priority. Their wholly dedicated research facility just outside of Charlotte, North Carolina hosts a study team with extensive clinical trial expertise, ranging from Phase I trials to high-volume bioequivalence studies. MBR’s white-glove service and commitment to diversity made it the ideal platform investment for New Harbor Capital to participate in the rapidly evolving clinical research site market.

Crosstree’s Role

Crosstree’s expertise in the clinical trial site industry and deep understanding of MBR’s unique value proposition helped the firm advise MBR in identifying New Harbor Capital as the ideal transaction partner through:

• Presenting MBR’s unique value proposition to help them achieve the optimal outcome
• Assessing multiple competitive offers received from a group of hand-picked potential buyers so buyer could base decision on real data, not hypothesis
• Leveraging market expertise and existing relationships to identify the ideal partner to maximize synergies and exceed MBR’s expectations